Pharming Group N.V. announces that the first patient has been dosed in its Phase III pediatric clinical trial evaluating a new pediatric formulation of the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta inhibitor, in children ages one to six years, with activated phosphoinositide 3-kinase delta syndrome.
